RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
The purpose of the study is to collect information on how Ryzodeg® works in real world
 participants. Participants will get Ryzodeg® as prescribed to them by the study doctor. The
 study will last for about 6 to 8 months. The participants will be asked questions about their
 health and their diabetes treatment as part of their normal study doctor's appointment.
Inclusion Criteria:

 -  Informed consent obtained before any study-related activities. Study-related
 activities are any procedures related to recording of data according to the protocol

 -  The decision to initiate treatment with commercially available insulin Ryzodeg® has
 been made by the patient/legally acceptable representative and the treating physician
 before and independently from the decision to include the patient in this study

 -  Male or female, age more than or equal to 20 years (the legal age of adulthood) at the
 time of signing informed consent

 -  Diagnosed with type 2 diabetes (T2D) for at least 26 weeks prior to signing informed
 consent

 -  Available and documented glycosylated haemoglobin (HbA1c) value less than or equal to
 12 weeks prior to initiation of Ryzodeg® treatment

 -  For at least 26 weeks prior to initiation of Ryzodeg® treatment, one of the following
 must apply: A) Treated with insulin glargine (IGlar) (any formulation, including
 biosimilar IGlar). B) Treated with IGlar (any formulation, including biosimilar IGlar)
 and IGlar U300 for at least 12 weeks prior to initiation of Ryzodeg®

 Exclusion Criteria:

 -  Previous participation in this study. Participation is defined as signed informed
 consent.

 -  Pregnancy

 -  Mental incapacity, unwillingness or language barriers precluding adequate
 understanding or cooperation

 -  Hypersensitivity to Ryzodeg® or to any of the excipients

 -  Previously treated with Ryzodeg®